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biology
Abstract
As synthetic biology develops into a promising science and engineering field, we need to have clear
ideas and priorities regarding its safety, security, ethical and public dialogue implications. Based on an
extensive literature search, interviews with scientists, social scientists, a 4 week long public e-forum,
and consultation with several stakeholders from science, industry and civil society organisations, we
compiled a list of priority topics regarding societal issues of synthetic biology for the years ahead. The
points presented here are intended to encourage all stakeholders to engage in the prioritisation of these
issues and to participate in a continuous dialogue, with the ultimate goal of providing a basis for a
multi-stakeholder governance in synthetic biology. Here we show possible ways to solve the challenges
to synthetic biology in the field of safety, security, ethics and the science-public interface.
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Abstract As synthetic biology develops into a promising
science and engineering field, we need to have clear ideas
and priorities regarding its safety, security, ethical and
public dialogue implications. Based on an extensive liter-
ature search, interviews with scientists, social scientists, a
4 week long public e-forum, and consultation with several
stakeholders from science, industry and civil society
organisations, we compiled a list of priority topics regard-
ing societal issues of synthetic biology for the years ahead.
The points presented here are intended to encourage all
stakeholders to engage in the prioritisation of these issues
and to participate in a continuous dialogue, with the ulti-
mate goal of providing a basis for a multi-stakeholder
governance in synthetic biology. Here we show possible
ways to solve the challenges to synthetic biology in the field
of safety, security, ethics and the science–public interface.
Keywords Synthetic biology  Governance  Biosafety 
Biosecurity  Ethics  Science  Society
Introduction
The following priority paper has arisen from our 2-year
European project SYNBIOSAFE (http://www.synbiosafe.eu),
studying the ethical, safety and security aspects of synthetic
biology. Based on an extensive literature search, interviews
with scientists, social scientists, civil societies (Kelle 2007;
Ganguli-Mitra et al 2009), a 4 week long public e-forum
(Schmidt et al. 2008a), and consultation with several stake-
holders (Schmidt et al. 2008b), the authors of this paper have
compiled what they consider to be priority topics regarding
societal issues of synthetic biology for the years ahead. The
points collected below are intended to encourage all stake-
holders to react to the various issues presented, to engage in
the prioritization of these issues and to participate in a con-
tinuous dialogue, with the ultimate goal of providing a basis
for a multi-stakeholder governance of this field. The points
presented here might serve as well as a decision support for
national and international funding agencies regarding future
research on key societal aspects of synthetic biology. Last
but not least we hope to enhance the discussion over the
issues addressed.
Synthetic biology is the design and construction of new
biological systems not found in nature. Synthetic biology as
a scientific label currently includes the following subfields:
(A) Engineering DNA-based biological circuits, including
but not limited to standardized biological parts; (B) Defin-
ing a minimal genome/minimal life (top-down); (C)
M. Schmidt (&)  A. Kelle
Biosafety Working Group, Organisation for International
Dialogue and Conflict Management, Kaiserstr. 50/6,
1070 Vienna, Austria
e-mail: markus.schmidt@idialog.eu
URL: www.idialog.eu
A. Ganguli-Mitra  N. Biller-Andorno
Institute of Biomedical Ethics, University of Zurich,
Zollikerstr. 115, 8008 Zurich, Switzerland
H. Torgersen
Institute of Technology Assessment, Austrian Academy
of Sciences, Strohgasse, 45, 1030 Vienna, Austria
A. Kelle
Department of European Studies and Modern Languages,
University of Bath, Claverton Down, Bath BA2 7AY, UK
A. Deplazes
University Research Priority Programme (URPP) in Ethics,
University of Zurich, Klosbachstr. 107, 8032 Zurich,
Switzerland
123
Syst Synth Biol (2009) 3:3–7
DOI 10.1007/s11693-009-9034-7
Constructing protocells, i.e. living cells, from scratch
(bottom-up); (D) Creating orthogonal biological systems
based on a biochemistry not found in nature, e.g. non-
ATGC DNA bases or non-DNA non-RNA nucleic acids, so
called XNA (Xenonucleic acid) (Benner and Sismour 2005;
O’Malley et al. 2008; Schmidt 2009; Herdewijn and
Marliere 2009; Deplazes 2009). Also relevant to synthetic
biology is a supporting technology, the chemical synthesis
of DNA. Synthetic biology aims at creating novel organ-
isms for practical purposes but also at gaining insights into
living systems by re-constructing them. Synthetic biology is
developing rapidly as a new branch of biotechnology, with
many anticipated benefits and a high impact on society. As a
result, the societal aspects of this discipline, as well as its
possible risks, are becoming increasingly prominent. It is
therefore crucial that the societal dimensions develop side
by side with the field, engaging all stakeholders, including
scientists, other experts and society at large.
The points made here address these dimensions in two
ways. First they deal with novel issues that accompany
synthetic biology, which are different from those associated
with other life science activities. Second they also deal with
the fact that ‘‘old’’ issues will resurface in the discussion of
societal aspects of synthetic biology. Although some of the
topics have been discussed for 30 years now (e.g. since
Asilomar), the contemporary political and societal contexts
are quite different compared to the mid-1970s (Berg 2008;
Deplazes et al. 2009). Thus old issues may be renegotiated
in the light of this contemporary context.
Societal issues in synthetic biology: a priority list
Below we present and discuss four major societal topics in
synthetic biology: safety, security, ethics and the science-
society interface. A brief overview is given for each soci-
etal topic that reflects the outcome of the SYNBIOSAFE
project and the consultation process with several stake-
holders (see ‘‘Acknowledgements’’).
Safety
These points deal with the prevention of unintentional expo-
sure to pathogens, toxins and otherwise harmful or potentially
harmful biological material, or its accidental release.
New methods in risk assessment
Synthetic biology requires new methods of risk assessment
to decide whether a new synthetic biology technique or
application is safe enough (for human health, animals and
the environment) for the use in restricted and/or less
restricted environments. The following cases warrant a
review and adaptation of current risk assessment practices:
(A) DNA-based biocircuits consisting of a larger number of
DNA ‘parts’; (B) The survivability and evolvability of novel
minimal organisms—used as platform/chassis for DNA
based biocircuits—in different environments; and (C) Exo-
tic biological systems based on an alternative biochemical
structure, e.g. genetic code based on novel types of nucle-
otides, or an enlarged number of base pairs (NIH 2009;
Schmidt et al 2008a; Schmidt 2009; Schmidt et al. 2009).
Synthetic safety systems (biosafety engineering)
An important task of a safety discussion is to explore how
synthetic biology itself may contribute towards overcoming
existing and possible future biosafety problems by contributing
to the design of safer biosystems, for example: (A) Design of
less competitive organisms by changing metabolic pathways;
(B) Replacing metabolic pathways with others that have an
in-built dependency on external biochemicals; (C) Design of
evolutionary robust biological circuits; (D) Use of biological
systems based on an alternative biochemical structure to avoid
e.g. gene flow to and from wild species; (E) Design of proto-
cells that lack key features of living entities, such as growth
or replication (Schmidt 2009; Herdewijn and Marliere 2009).
Diffusion of synthetic biology to amateur biologists
Careful attention must be paid to the way synthetic biology
skills diffuse (e.g. Do-it-yourself biology, amateurs, bio-
hackers). The consequences of further deskilling biotech-
nology are not clear and should be investigated. In particular:
(A) Care must be taken to ensure that everyone using the
resources of synthetic biology does so safely and has suffi-
cient awareness of and training in relevant biosafety tech-
niques and approaches; (B) Proper mechanisms such as laws,
codes of conduct, voluntary measures, access restrictions to
key materials, institutional embedding and mandatory
reporting to Institutional Biosafety Committees [IBCs], need
to be in place to avoid unintentional harm (Schmidt 2008).
Security
These points deal with the prevention of misuse through for
example loss, theft, diversion or intentional release of
pathogens, toxins and other biological materials. Among
the core areas of our research it is the security aspect that
has been mostly absent from past discussions of the soci-
etal implications of the revolution in the life sciences.
Awareness
While biosecurity awareness among European DNA syn-
thesis companies is comparatively high, among most
4 M. Schmidt et al.
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European synthetic biology scientists it still is very low
(Kelle 2007). Their awareness needs to be further enhanced
through better communication and cooperation between the
synthetic biology and biosecurity communities (NSABB
2008).
Education
Based on increased cooperation and communication among
the synthetic biology and biosecurity communities, issues
beyond the dual-use problem, such as the past misuse of the
life sciences for offensive bioweapons programmes, secu-
rity-related inadvertent research results, and the existence
and operation of the Biological Weapons Convention
should be systematically included in undergraduate biology
curricula (Mancini and Revill 2008).
Governance and oversight
Addressing questions of governance and oversight of bio-
security will require more regulatory tools than dealing
with other societal issues. In order to avoid too severe
restrictions resulting from an oversight system, the con-
tinued and expanded involvement of all stakeholders is
required (Anon 2008; Garfinkel et al. 2007; Kelle 2009).
Technical solutions
Some biosecurity challenges need immediate technical
attention, as well as solutions to be further developed and
implemented. This includes, in particular: (A) the cooper-
ation of DNA synthesis companies (that produce gene- or
genome-length DNA) in screening orders to avoid inad-
vertent production of certain select agents and/or parts
thereof, (B) further developing and improving the technical
means (e.g. software, databases) used to screen for DNA
orders and (C) when expanding current efforts in these
areas, such as to include shorter DNA strands, and possibly
equipment such as DNA synthesizers in the future, a bal-
ance will need to be struck between security gains on one
hand and practicability and usefulness on the other (Ber-
nauer et al. 2008; Nouri and Chyba 2009).
Ethics
These points deal with normative aspects of procedures,
applications and the distribution of synthetic biology.
Designing and creating life
The aim to design and create new forms of life raises per se
certain ethical questions related to the relationship between
humans and other living organisms and the moral status of
the products of synthetic biology. Along the same line
further societal discussion is required on various concep-
tions of life. Although such discussions are unlikely to
reach global consensus, a social and philosophical inves-
tigation that aims at including a variety of worldviews is
necessary, with particular attention being given to the
normative implications arising from different conceptions
of life (Ganguli-Mitra et al. 2009; Parens et al. 2008; Boldt
and Mu¨ller 2008, 2009; Schmidt et al. 2009; Deplazes et al.
2009).
Assessing risks and benefits
An open and engaged ethical debate is needed on the moral
acceptability of the risks and the equitable distribution of
risks and benefits arising from various techniques and
applications, in particular those requiring the interaction of
natural and synthetic organisms, as well as the implications
of such interaction for human health, animal health and for
the environment.
Benefits, access and justice
Further discussion should be encouraged on the distribution
of products and knowledge arising from synthetic biology
research, in particular as they relate to various aspects of
social justice, power relations and the current global divide.
Particular attention should be given to the debate about
intellectual property rights and the effect of such rights on
access to the products and knowledge of synthetic biology
(Rai and Boyle 2007; Henkel and Maurer 2007; ETC 2007,
2008).
Science-public interface
Education
Societal topics related to synthetic biology, such as safety,
security and ethical issues as discussed should be incor-
porated into the teaching curricula of synthetic biologists
from the very early days of their education.
Public engagement
Rendering scientists aware of such issues is a necessary
condition but not sufficient to ensure that they are dealt with
adequately. As synthetic biology develops into an applied
technology, it is important that scientists, stakeholders and
the public communicate in an interactive way. Past debates
on genetic engineering suggest that in order to omit exag-
gerated hopes and fears, scientists should adopt an open
approach towards the public and that stakeholders need to
be responsive to scientific arguments. Both stakeholders
Societal and ethical aspects of synthetic biology 5
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and scientists should engage in ethical discussions with
members of the public, going beyond mere campaigning or
conveying of factual information. Views of the public
reflecting public preferences and situated knowledge
(embedded in language, culture, or traditions) need to be
taken seriously, even if experts consider them to be misin-
formed. Different interests and world-views associated with
technology and innovation, need to be addressed and not to
be dismissed as unscientific.
Stakeholder involvement
Since developments in synthetic biology are so rapid and
regulation alone is no guarantee against misuse or societal
controversies, it is necessary to involve relevant stake-
holders in the decision-making process. This allows for a
flexible and relatively swift way of dealing with upcoming
problems through a combination of regulations, agree-
ments, codes of conduct etc. and entails a distribution of
responsibilities. A multi-stakeholder approach for the
governance of synthetic biology and its applications should
involve scientists, regulators, members of civil society,
industry representatives, philosophers, and other relevant
groups (Ganguli-Mitra et al. 2009; Stemerding et al. 2009).
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